| Abstrakt: |
Introduction: Renal failure-related mortality is significantly elevated among Rheumatoid Arthritis (RA) patients, with a documented prevalence of renal disease in approximately 72% of cases. The reported prevalence of kidney disease in RA varies widely, making its true prevalence uncertain. RA is associated with kidney disorders attributed to chronic inflammation and drug exposure. This study aims to explore serum biochemical abnormalities in RA, focusing on urea, creatinine, and erythrocyte sedimentation rate (ESR), particularly in response to NSAID treatment. Material and Methods: The study, conducted in Sambalpur City, included 180 volunteers categorized into three groups: Control (healthy individuals), Group I (RA patients), and Group II (RA patients using NSAIDs). Blood samples were collected for urea, creatinine, and ESR analysis. Data were presented as mean ± SD, and the significance of mean differences was assessed using the student's t-test. Results: Significant variations were observed in ESR, urea, and creatinine levels among the groups. ESR levels surged in RA patients, with NSAID use exhibiting a notable rise. Urea and creatinine levels increased in RA patients, showing a slight decrease after NSAID treatment. These alterations highlight distinct biochemical changes in RA patients and those using NSAIDs compared to the healthy Control Group. Discussion: The study illuminates the intricate links between Rheumatoid Arthritis (RA), renal health, and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Elevated Erythrocyte Sedimentation Rate (ESR), increased serum creatinine and urea levels in RA patients, and the potential renal impact of NSAIDs underscore the need for nuanced therapeutic approaches and vigilant monitoring in managing RA, shaping future research directions. Conclusion: Findings underscore the need for vigilant monitoring and personalized therapeutic strategies in managing RA patients, particularly those undergoing NSAID treatment. This research lays a foundation for future investigations into tailored clinical interventions and a comprehensive understanding of the complexities of managing RA patients with renal implications. [ABSTRACT FROM AUTHOR] |
